Transcutaneous Immunization with Cross-Reacting Material CRM197 of Diphtheria Toxin Boosts Functional Antibody Levels in Mice Primed Parenterally with Adsorbed Diphtheria Toxoid Vaccine

ABSTRACT Transcutaneous immunization (TCI) capitalizes on the accessibility and immunocompetence of the skin, elicits protective immunity, simplifies vaccine delivery, and may be particularly advantageous when frequent boosting is required. In this study we examined the potential of TCI to boost preexisting immune responses to diphtheria in mice. The cross-reacting material (CRM197) of diphtheria toxin was used as the boosting antigen and was administered alone or together with either one of two commonly used mucosal adjuvants, cholera toxin (CT) and a partially detoxified mutant of heat-labile enterotoxin of Escherichia coli (LTR72). We report that TCI with CRM197 significantly boosted preexisting immune responses elicited after parenteral priming with aluminum hydroxide-adsorbed diphtheria toxoid (DTxd) vaccine. In the presence of LTR72 as an adjuvant, toxin-neutralizing antibody titers were significantly higher than those elicited by CRM197 alone and were comparable to the functional antibody levels induced after parenteral booster immunization with the adsorbed DTxd vaccine. Time course study showed that high levels of toxin-neutralizing antibodies persisted for at least 14 weeks after the transcutaneous boost. In addition, TCI resulted in a vigorous antigen-specific proliferative response in all groups of mice boosted with the CRM197 protein. These findings highlight the promising prospect of using booster administrations of CRM197 via the transcutaneous route to establish good herd immunity against diphtheria.

[1]  W. Jiskoot,et al.  Immune Modulation by Adjuvants Combined with Diphtheria Toxoid Administered Topically in BALB/c Mice After Microneedle Array Pretreatment , 2009, Pharmaceutical Research.

[2]  S. Rijpkema,et al.  New adjuvants: EU regulatory developments , 2007, Expert review of vaccines.

[3]  G. Glenn,et al.  Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch , 2007, Expert review of vaccines.

[4]  T. D. Connell,et al.  Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by Type I and Type II heat-labile enterotoxins , 2007, Expert review of vaccines.

[5]  E. Hoster,et al.  Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. , 2006, Vaccine.

[6]  S. Muller,et al.  Effect of Skin Barrier Disruption on Immune Responses to Topically Applied Cross-Reacting Material, CRM197, of Diphtheria Toxin , 2005, Infection and Immunity.

[7]  I. Sjöholm,et al.  Mucosal vaccination against diphtheria using starch microparticles as adjuvant for cross-reacting material (CRM197) of diphtheria toxin. , 2005, Vaccine.

[8]  R. Rappuoli,et al.  Successful induction of protective antibody responses against Haemophilus influenzae type b and diphtheria after transcutaneous immunization with the glycoconjugate polyribosyl ribitol phosphate-cross-reacting material 197 vaccine. , 2004, The Journal of infectious diseases.

[9]  E. B. Lindblad.  Aluminium adjuvants--in retrospect and prospect. , 2004, Vaccine.

[10]  G. Glenn,et al.  Induction of protective immunity against lethal anthrax challenge with a patch. , 2004, The Journal of infectious diseases.

[11]  S. Clare,et al.  Mucosal Vaccination against Serogroup B Meningococci: Induction of Bactericidal Antibodies and Cellular Immunity following Intranasal Immunization with NadA of Neisseria meningitidis and Mutants of Escherichia coli Heat-Labile Enterotoxin , 2004, Infection and Immunity.

[12]  S. Muller,et al.  Modulation of immune responses with transcutaneously deliverable adjuvants. , 2004, Vaccine.

[13]  Robert T. Chen,et al.  Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. , 2004, The New England journal of medicine.

[14]  R. Rappuoli,et al.  Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. , 2004, Vaccine.

[15]  R. Rappuoli,et al.  Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. , 2003, The Journal of infectious diseases.

[16]  K. Buchheit,et al.  Collaborative study for establishment of the European Pharmacopoeia BRP batch 1 for diphtheria toxin. , 2003, Pharmeuropa bio.

[17]  G. Glenn,et al.  Immunostimulant Patch Containing Heat-Labile Enterotoxin from Escherichia coli Enhances Immune Responses to Injected Influenza Virus Vaccine through Activation of Skin Dendritic Cells , 2003, Journal of Virology.

[18]  G. Glenn,et al.  Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin , 2003, Expert review of vaccines.

[19]  R. Rappuoli,et al.  Protective Levels of Diphtheria-Neutralizing Antibody Induced in Healthy Volunteers by Unilateral Priming-Boosting Intranasal Immunization Associated with Restricted Ipsilateral Mucosal Secretory Immunoglobulin A , 2003, Infection and Immunity.

[20]  R. Rappuoli,et al.  The LTR72 Mutant of Heat-Labile Enterotoxin of Escherichia coli Enhances the Ability of Peptide Antigens To Elicit CD4+ T Cells and Secrete Gamma Interferon after Coapplication onto Bare Skin , 2002, Infection and Immunity.

[21]  M. Wolf,et al.  Safety and Immunogenicity of a Prototype Enterotoxigenic Escherichia coli Vaccine Administered Transcutaneously , 2002, Infection and Immunity.

[22]  A. Efstratiou,et al.  Report on the Sixth International Meeting of the European Laboratory Working Group on Diphtheria, Brussels, Belgium. , 2002, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[23]  P. Rigsby,et al.  A Vero cell method for potency testing of diphtheria vaccines. , 2002, Developments in biologicals.

[24]  P. Rigsby,et al.  Calibration of replacement international standard and European Pharmacopoeia Biological Reference Preparation for Diphtheria Toxoid, Adsorbed. , 2001, Biologicals : journal of the International Association of Biological Standardization.

[25]  R. Rappuoli,et al.  A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. , 2000, Vaccine.

[26]  C. Alving,et al.  Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins, Subunits, and Unrelated Adjuvants , 2000, Infection and Immunity.

[27]  A. Galazka,et al.  Implications of the diphtheria epidemic in the Former Soviet Union for immunization programs. , 2000, The Journal of infectious diseases.

[28]  G. Dougan,et al.  Mucosal Adjuvanticity and Immunogenicity of LTR72, a Novel Mutant of Escherichia coli Heat-labile Enterotoxin with Partial Knockout of ADP-ribosyltransferase Activity , 1998, The Journal of experimental medicine.

[29]  R. Rappuoli,et al.  Differences in the immunogenicity of native and formalinized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs. , 1997, Vaccine.

[30]  A. Galazka,et al.  Immunization against diphtheria with special emphasis on immunization of adults. , 1996, Vaccine.

[31]  N. Andrews,et al.  Diphtheria immunity in UK blood donors , 1995, The Lancet.

[32]  T. Mitamura,et al.  Diphtheria Toxin Binds to the Epidermal Growth Factor (EGF)-like Domain of Human Heparin-binding EGF-like Growth Factor/Diphtheria Toxin Receptor and Inhibits Specifically Its Mitogenic Activity (*) , 1995, The Journal of Biological Chemistry.

[33]  B. Spangler,et al.  Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. , 1992, Microbiological reviews.

[34]  Gary J. Nabel,et al.  New Generation Vaccines , 1990 .

[35]  R. Rappuoli,et al.  The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. , 1984, Nucleic acids research.